Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Candel Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −1 vs. Q4 2023
- Shares held
- 3.78M
- −170.0K (−4.3%) vs. Q4 2023
- Total value
- $5.97M
- +$166.1K (+2.9%) vs. Q4 2023
- New holders
- 4
- 6 more added
- Sold out
- 5
- 5 more reduced
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CADL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 137 | $518.9M |
| Q1 2026 | 114 | $212.9M |
| Q4 2025 | 84 | $133.5M |
| Q3 2025 | 81 | $115.6M |
| Q2 2025 | 78 | $116.6M |
| Q1 2025 | 82 | $119.7M |
| Q4 2024 | 71 | $155.7M |
| Q3 2024 | 52 | $46.4M |
| Q2 2024 | 45 | $37.0M |
| Q1 2024 | 20 | $5.97M |
| Q4 2023 | 22 | $5.92M |
| Q3 2023 | 20 | $4.86M |
| Q2 2023 | 20 | $6.77M |
| Q1 2023 | 21 | $7.44M |
| Q4 2022 | 21 | $9.70M |
| Q3 2022 | 25 | $19.1M |
| Q2 2022 | 23 | $20.6M |
| Q1 2022 | 23 | $34.0M |
| Q4 2021 | 20 | $54.4M |
| Q3 2021 | 12 | $52.9M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Candel Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Northpond Ventures, LLC | 1,935,215 | $3.06M | 2.98% | 00.0% | Unchanged |
| Sands Capital Ventures, LLC | 811,737 | $1.28M | 0.31% | 00.0% | Unchanged |
| Vanguard Group Inc | 541,295 | $855.2K | 0.00% | +115,546+27.1% | Added |
| Geode Capital Management, LLC | 145,706 | $230.3K | 0.00% | +6,453+4.6% | Added |
| Bridgeway Capital Management, LLC | 82,595 | $130.5K | 0.00% | −50,000−37.7% | Reduced |
| Renaissance Technologies LLC | 56,905 | $90.0K | 0.00% | +38,230+204.7% | Added |
| BlackRock Inc. | 47,580 | $75.2K | 0.00% | −1,705−3.5% | Reduced |
| Mariner, LLC | 33,480 | $52.9K | 0.00% | +33,480 | New |
| Resources Investment Advisors, LLC. | 29,783 | $47.1K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 27,600 | $43.6K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 19,507 | $30.8K | 0.00% | −110−0.6% | Reduced |
| Traphagen Investment Advisors LLC | 17,215 | $27.2K | 0.00% | +17,215 | New |
| Commonwealth Equity Services, LLC | 14,182 | $22.0K | 0.00% | +14,182 | New |
| Two Sigma Investments, LP | 13,409 | $21.2K | 0.00% | +13,409 | New |
| Tower Research Capital LLC (TRC) | 3,702 | $5.85K | 0.00% | −3,031−45.0% | Reduced |
| JPMorgan Chase & Co | 221 | $349 | 0.00% | +12+5.7% | Added |
| Wells Fargo & Company | 115 | $182 | 0.00% | +2+1.8% | Added |
| UBS Group AG | 10 | $16 | 0.00% | −11,911−99.9% | Reduced |
| Qube Research & Technologies Ltd | 1 | $2 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 69 | $0 | 0.00% | +39+130.0% | Added |
| FMR LLC | 0 | $0 | 0.00% | −298,384−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −16,852−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −16,510−100.0% | Sold out |
| Vontobel Holding Ltd. | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| Baystate Wealth Management LLC | – | – | – | – | Not filed |